The effect of antipsychotics on bone mineral density and sex hormones in male patients with schizophrenia

Psychiatria Danubina

Volumn 28, Issue 3, 2016, Pages 255-262

  Doǧan Bulut, Süheyla ^a   Bulut, Serdar ^b   Görkem Atalan, Dicle ^a   Tulaci, Riza Gökçer ^a   Türker, Türker ^c   Gürçay, Eda ^a   Çiǧdem, Aydemir ^d  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Yenimahalle Training and Research Hospital Anesthesiology and Reanimation Clinics   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d Numune Teaching and Research Hospital   (Turkey)

Author keywords

Antipsychotics; Bone mineral density; Osteoporosis; Schizophrenia

Indexed keywords

CHLORPROMAZINE; ESTRADIOL; HALOPERIDOL; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; TESTOSTERONE; NEUROLEPTIC AGENT; SEX HORMONE;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPERPROLACTINEMIA; LONGITUDINAL STUDY; MALE; MIDDLE AGED; OSTEOPENIA; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SCHIZOPHRENIA; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLIC BONE DISEASE; REFERENCE VALUE; STATISTICS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; PROLACTIN; REFERENCE VALUES; SCHIZOPHRENIA; STATISTICS AS TOPIC; TESTOSTERONE; YOUNG ADULT;

EID: 84989841564     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E & Josiassen RC: Effects of elevated serum prolactin on bone mineral density and bone metabolismin female patients with schizophrenia: a prospective study. Am J Psychiatry 2003; 160:1618-20.
2. American Psychiatric Association: Diagnostic criteria from DSM-IV-TR. American Psychiatric Pub, 2000.
3. Becker D, Liver O, Mester R, Rapoport M, Weizman A & Weiss M: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003; 64: 761-7.
4. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M & Tan U: Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002; 112:817-28.
5. Bridges RS, Numan M, Ronsheim PM, Mann PE & Lupini CE: Central prolactin infusions stimulate maternal behavior in steroid-treated, nulliparous female rats. Proc Natl Acad Sci 1990; 87:8003-7.
6. Bulut SD, Bulut S, Tuzer V, Ak M, Ak E, Kisa C et al.: The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients. Archives of Neuropsychiatry 2014; 51:205-10.
7. Dickson RA, Seman MV & Corenblum B: Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry 1999; 61:10-15.
8. Freeman ME, Kanyicska B, Lerant A & Nagy G: Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80:1523-631.
9. Goffin V, Binart N, Touraine P & Kelly PA: Prolactin: the new biology of an old hormone. Annu Rev Physiol 2002; 64:47-67.
10. Haddad PM & Wieck A: Antipsychotic-induced hyperprolactinaemia. Drugs 2004; 64:2291-314.
11. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y et al.: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57:485-91.
12. Hert M, Correll CU, Bobes CU, Cetkovich-Bakmas M, Cohen D, Asai I et al: Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in healthcare. World Psychiatry 2011; 10:52-77.
13. Hert M, Detraux J, van Winkel R, Yu W & Correll CU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8:114-26.
14. Hummer M, Malik P, Gasser RW, Hofer A, Kemmler G & Moncayo Naveda RC: Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005; 162:162-7.
15. Javaid MK & Holt RI: Understanding osteoporosis. J Psychopharmacol 2008; 22:38-45.
16. Kane JM & Correll CU: Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71:1115-24.
17. Keely EJ, Reiss JP, Drinkwater DT & Faiman C: Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men. Endocr Pract 1997; 3:209-13.
18. Kinon BJ, Gilmore JA, Liu H & Halbreich UM: Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28:55-68.
19. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT & McArthur JW: Decreased bone density in hyperprolactinemic women N Engl J Med 1980; 303:1511-4.
20. Lee TY, Chung MY, Chung HK, Choi JH, Kim TY & So HS: Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study. Psychiatry Investig 2010; 7: 278-84.
21. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM & O'Keane V: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184:503-8.
22. Meaney AM & O'Keane V: Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007; 93:136-43.
23. Melton LJ: Epidemiology of fractures. In: Riggs BL & Melton LJ (eds): Osteoporosis: Etiology, Diagnosis and Management, second edition, 225-47. Lippincott-Raven Publishers, Philadelphia, 1995.
24. Motyl KJ, Dick-de-Paula I, Maloney AE, Lotinun S, Bornstein S, de Paula FJ et al.: Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone 2012; 50:490-8.
25. Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D & Violante AH: Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 2005; 28:12-7.
26. O'Keane V & Meaney AM: Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?. J Clin Psychopharmacol 2005; 25:26-31.
27. Renn JH, Yang NP & Chou P: Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet Disord 2010; 11: 35.
28. Rey-Sanchez P, Lavado-Garcia JM, Canal-Macias ML, Gomez-Zubeldia MA, Roncero-Martin R & Pedrera- Zamorano JD: Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol 2009; 24:49-54.
29. Roke Y, van Harten PN, Boot AM & Buitelaar JK: Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 2009; 19:403-14.
30. Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, Teerapornpuntakit J et al.: Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kB ligand/osteoprotegerin ratio. Bone 2008; 42:535-46.
31. Smith S, Wheeler M, Murray R & O'Keane V: The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002; 22:109-14.
32. Sugawara N, Yasui-Furukori N, Fujii A, Saito M, Sato Y, Nakagami T et al.: No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol 2011; 26:596-601.
33. Wang M, Hou R, Jian J, Mi G, Qiu H, Cao B et al: Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol 2014; 29:183-9.
34. WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363:157-63.
35. Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64:663-7.
36. World Health Organization: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser 1994; 843:1-129.